import Link from "next/link";
import { Callout, Checklist, DataTable } from "@/components/insights/Prose";
import type { Post } from "./types";

export const pharmacovigilanceSoftwareBuildVsBuy: Post = {
  slug: "pharmacovigilance-software-build-vs-buy",
  title: "Pharmacovigilance software: build vs buy",
  metaTitle: "Pharmacovigilance Software: Build vs Buy",
  description:
    "Build or buy a pharmacovigilance system? Case intake, MedDRA coding and licensing, E2B(R3) reporting, signal detection, validation and AI-assisted intake.",
  excerpt:
    "Should a drug-safety team build its own pharmacovigilance system or buy one? What the software must do, where the hard parts are, and how AI-assisted intake fits safely.",
  category: "Regulated software",
  pillar: "regulated",
  cover: "audit",
  published: "2026-09-28",
  readingMinutes: 8,
  keywords: [
    "pharmacovigilance software",
    "pharmacovigilance software build vs buy",
    "safety database software",
    "E2B R3 reporting software",
    "MedDRA coding software",
    "AI in pharmacovigilance case intake",
    "pharmacovigilance software India",
    "drug safety software development",
  ],
  takeaways: [
    "Most companies should buy or subscribe to a proven safety database; building makes sense only for unusual workflows, a product you plan to sell, or deep integration needs.",
    "The hard parts are compliance-grade: E2B(R3) exchange, MedDRA coding, reporting timelines, audit trails and validation.",
    "MedDRA needs a subscription for commercial use — budget for it whether you build or buy.",
    "AI can speed up case intake and coding suggestions, but a qualified person should review and approve every case.",
  ],
  intro: (
    <>
      <p>
        Most marketing authorisation holders and service providers should buy or
        subscribe to a validated pharmacovigilance system rather than build one.
        Build only when your workflow is unusual, you need deep integrations, or
        the software is itself your product. Either way, check E2B(R3)
        reporting, MedDRA coding, audit trails, validation evidence and how AI
        is supervised.
      </p>
      <p>
        Pharmacovigilance software sits under close regulatory scrutiny: late or
        wrong safety reports are inspection findings. This guide walks through
        what the system must do, the build-or-buy trade-offs, and how
        AI-assisted intake can help without taking people out of the loop.
      </p>
    </>
  ),
  sections: [
    {
      id: "what-the-system-does",
      title: "What pharmacovigilance software must do",
      body: (
        <>
          <DataTable
            caption="Core functions of a pharmacovigilance system"
            head={["Function", "What it involves"]}
            rows={[
              [
                "Case intake",
                "Receiving adverse event reports from email, forms, call centres, literature, partners and regulators; duplicate checks",
              ],
              [
                "Case processing",
                "Data entry, seriousness and expectedness assessment, causality, narratives, medical review",
              ],
              [
                "Coding",
                "MedDRA for events and medical history; a drug dictionary such as WHODrug for products",
              ],
              [
                "Regulatory reporting",
                "ICSRs in ICH E2B(R3) format to regulators and partners, within required timelines",
              ],
              [
                "Aggregate reports",
                "Data outputs for periodic reports such as PSURs/PBRERs",
              ],
              [
                "Signal detection",
                "Reviewing case data for new or changing safety signals, and tracking signal evaluation",
              ],
              [
                "Compliance and audit",
                "Audit trails, electronic signatures, access control, submission tracking and metrics",
              ],
            ]}
          />
          <p>
            Every one of these carries regulatory weight, which is why the
            build-or-buy decision is really about who carries the compliance
            burden.
          </p>
        </>
      ),
    },
    {
      id: "build-vs-buy",
      title: "Build vs buy, side by side",
      body: (
        <>
          <DataTable
            caption="Building vs buying a pharmacovigilance system"
            head={["Factor", "Buy or subscribe", "Build (custom)"]}
            rows={[
              [
                "Time to go live",
                "Weeks to months, mostly configuration and validation",
                "Many months, including design, build and full validation",
              ],
              [
                "E2B(R3) and gateways",
                "Usually built in and maintained by the vendor",
                "You build, test and maintain the message handling yourself",
              ],
              [
                "Regulatory change",
                "Vendor updates for new rules and standard versions",
                "Your team tracks and implements every change",
              ],
              [
                "Workflow fit",
                "Configurable within the product’s design",
                "Exactly your workflow",
              ],
              [
                "Validation",
                "Configured system; vendor evidence can be leveraged",
                "Full Category 5 life cycle",
              ],
              [
                "Cost profile",
                "Subscription or licence plus implementation",
                "Higher upfront cost plus ongoing development and upkeep",
              ],
              [
                "Ownership",
                "Vendor roadmap; data export terms matter",
                "You own the code and roadmap",
              ],
            ]}
          />
          <h3>When building makes sense</h3>
          <ul>
            <li>
              You are a PV service provider or technology company and the
              software is your product.
            </li>
            <li>
              You need a custom layer — intake portals, partner exchanges or
              analytics — around an existing safety database.
            </li>
            <li>
              Your case volume, product mix or partner model doesn’t fit
              available products without heavy workarounds.
            </li>
          </ul>
          <p>
            For many teams, the middle path works: keep a proven safety database
            and build integrations or intake tools around it. Our{" "}
            <Link href="/insights/custom-software-vs-saas">
              custom software vs SaaS guide
            </Link>{" "}
            covers that hybrid approach in general terms.
          </p>
        </>
      ),
    },
    {
      id: "meddra-and-coding",
      title: "MedDRA coding and licensing",
      body: (
        <>
          <p>
            MedDRA, the Medical Dictionary for Regulatory Activities, is the
            standard terminology for coding adverse events in regulatory safety
            reporting. It is owned by ICH and maintained by its Maintenance and
            Support Services Organization (MSSO), with new versions released
            twice a year.
          </p>
          <Callout title="Licensing note">
            <p>
              Commercial organisations need a MedDRA subscription to use it;
              fees are set by MSSO and depend on the type and size of the
              organisation, while regulators and some non-profit and academic
              users have different terms. Your software vendor cannot normally
              cover your licence for you. Drug dictionaries such as WHODrug are
              licensed separately, too. Check current terms with the licensors
              directly.
            </p>
          </Callout>
          <p>Whether you build or buy, the system should:</p>
          <ul>
            <li>
              Load new MedDRA versions and support version upgrades, including
              recoding where terms change.
            </li>
            <li>
              Code at the Lowest Level Term and show the full hierarchy up to
              System Organ Class.
            </li>
            <li>Keep a record of the version used for each coded term.</li>
          </ul>
        </>
      ),
    },
    {
      id: "e2b-reporting",
      title: "E2B(R3) reporting and timelines",
      body: (
        <>
          <p>
            ICH E2B(R3) defines the electronic format for individual case safety
            reports (ICSRs). Major regulators, including the EMA through
            EudraVigilance, use it, and regional implementation guides add their
            own rules on top of the core standard.
          </p>
          <p>What the software has to handle:</p>
          <Checklist
            items={[
              "Generating valid E2B(R3) XML, including regional rules for each regulator you report to.",
              "Importing E2B messages from partners and regulators, not only sending them.",
              "Acknowledgements — tracking whether each submission was accepted or rejected, and why.",
              "Due-date calculation from the day the company first knew of a valid case, with alerts before deadlines.",
              "Follow-up versions and nullifications linked to the original case.",
              "Submission history and compliance metrics you can show an inspector.",
            ]}
          />
          <p>
            Building this well is a significant piece of work on its own, and it
            needs testing against each regulator’s requirements. It is one of
            the strongest reasons to buy rather than build.
          </p>
        </>
      ),
    },
    {
      id: "signal-detection",
      title: "Signal detection",
      body: (
        <>
          <p>
            Signal detection looks across cases for new or changing risks.
            Common approaches combine:
          </p>
          <ul>
            <li>
              <strong>Case review</strong> — medical reviewers look at serious
              and unexpected cases and case series.
            </li>
            <li>
              <strong>Disproportionality analysis</strong> — statistics such as
              the proportional reporting ratio (PRR) or reporting odds ratio
              (ROR) highlight drug–event pairs reported more often than
              expected.
            </li>
            <li>
              <strong>External data</strong> — literature and regulator
              databases, where access is available.
            </li>
            <li>
              <strong>Signal management</strong> — recording each signal, its
              evaluation, decisions and actions, with an audit trail.
            </li>
          </ul>
          <p>
            Statistics flag candidates; qualified people decide whether a signal
            is real. The software’s job is to make that review efficient and
            traceable.
          </p>
        </>
      ),
    },
    {
      id: "validation",
      title: "Validation and data integrity",
      body: (
        <>
          <p>
            A pharmacovigilance system is a GxP computerised system. Expect to
            validate it using a risk-based approach such as GAMP 5, with
            controls for 21 CFR Part 11 and EU Annex 11 where they apply.
            Inspectors will usually look closely at:
          </p>
          <ul>
            <li>Audit trails on case data, coding and assessments.</li>
            <li>Electronic signatures on medical review and submission.</li>
            <li>
              Role-based access, including for partners and service providers.
            </li>
            <li>
              Correct due-date calculation and E2B output, tested against
              realistic cases.
            </li>
            <li>
              Change control for MedDRA upgrades, configuration changes and
              software releases.
            </li>
          </ul>
          <p>
            Buying a system doesn’t remove validation; it reduces it to your
            configuration and use, with vendor evidence leveraged. See our{" "}
            <Link href="/insights/gamp-5-software-validation-guide">
              GAMP 5 guide
            </Link>{" "}
            and{" "}
            <Link href="/insights/csv-vs-csa-computer-software-assurance">
              CSV vs CSA explainer
            </Link>
            .
          </p>
        </>
      ),
    },
    {
      id: "ai-assisted-intake",
      title: "AI-assisted intake, with human review",
      body: (
        <>
          <p>
            Case intake is where AI helps most today. Reports arrive as emails,
            PDFs, scanned forms and call notes, and much of the work is reading
            them and filling in fields. Language models can:
          </p>
          <ul>
            <li>
              Extract patient, reporter, product and event details into a draft
              case.
            </li>
            <li>
              Check the four minimum criteria for a valid case and flag what’s
              missing.
            </li>
            <li>
              Suggest MedDRA terms for reported events, for a coder to confirm.
            </li>
            <li>
              Flag possible duplicates and likely serious cases for priority
              review.
            </li>
          </ul>
          <p>To use AI safely in a regulated process:</p>
          <Checklist
            items={[
              <>
                <strong>A person reviews and approves every case</strong> — AI
                drafts, it doesn’t decide.
              </>,
              <>
                <strong>Show the source</strong> — each extracted field links
                back to the text it came from.
              </>,
              <>
                <strong>Measure accuracy</strong> on a representative test set
                before go-live and after each change.
              </>,
              <>
                <strong>Log AI suggestions and human edits</strong> in the audit
                trail.
              </>,
              <>
                <strong>Protect patient data</strong> — know where it is
                processed and that it isn’t used for model training.
              </>,
            ]}
          />
          <p>
            We built PVgenix, a pharmacovigilance SaaS with AI-assisted intake,
            on these principles: AI prepares the draft and a qualified reviewer
            approves it.
          </p>
        </>
      ),
    },
    {
      id: "next-steps",
      title: "Next steps",
      body: (
        <>
          <p>
            Start by listing your case volumes, sources, partners, regulators
            and reporting obligations, then check each option against them —
            including validation evidence and data export terms. If you’re
            weighing a new system, a custom intake layer or a way to add AI to
            an existing process, we can help you think it through. See our{" "}
            <Link href="/services/regulated-software">
              regulated software service
            </Link>
            , read how we use{" "}
            <Link href="/services/ai-agents">AI with human approval</Link>, or{" "}
            <Link href="/#contact">get in touch</Link>.
          </p>
        </>
      ),
    },
  ],
  faqs: [
    {
      q: "Should we build or buy pharmacovigilance software?",
      a: "Most companies should buy or subscribe to a validated safety database. Building makes sense for unusual workflows, a PV product you plan to sell, or custom intake and integration layers around an existing system.",
    },
    {
      q: "What is E2B(R3) in pharmacovigilance?",
      a: "ICH E2B(R3) is the international standard for the electronic exchange of individual case safety reports (ICSRs) between companies and regulators, with regional rules added by each regulator.",
    },
    {
      q: "Do we need a MedDRA licence for pharmacovigilance software?",
      a: "Commercial organisations need a MedDRA subscription from MSSO to use it, whether they build or buy their software. Fees depend on the type and size of the organisation.",
    },
    {
      q: "Can AI be used for adverse event case intake?",
      a: "Yes, AI can extract case details, check validity criteria and suggest MedDRA terms. A qualified person should review and approve every case, with AI suggestions and edits recorded in the audit trail.",
    },
    {
      q: "Does pharmacovigilance software need validation?",
      a: "Yes. It is a GxP computerised system, so it should be validated using a risk-based approach such as GAMP 5, with Part 11 and Annex 11 controls where they apply.",
    },
  ],
};
